Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. Its news flow centers on the clinical and regulatory progress of its lead candidate, zervimesine (CT1812), an investigational oral pill in development for Alzheimer’s disease, dementia with Lewy bodies (DLB) and related conditions.
News updates from Cognition Therapeutics frequently cover milestones in its Phase 2 clinical programs. These include results and analyses from the SHINE study in mild-to-moderate Alzheimer’s disease, the SHIMMER study in mild-to-moderate DLB, and the START study in early Alzheimer’s disease. Articles describe safety and tolerability outcomes, changes in cognition and function measured by validated scales, and exploratory findings in behavioral, movement and neuropsychiatric domains.
Investors following CGTX news also see announcements about expanded access programs for zervimesine in DLB, collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium, and substantial grant support from the National Institute on Aging of the National Institutes of Health. Regulatory and scientific updates, such as end-of-Phase 2 discussions with the U.S. Food and Drug Administration, Type C meeting plans, and presentations at major Alzheimer’s disease conferences, are regular features of the company’s news cycle.
In addition, Cognition Therapeutics issues press releases on financing transactions, including registered direct offerings of common stock and at-the-market equity programs, which provide context on how it funds ongoing and planned studies. For readers tracking CGTX, this news page consolidates clinical, regulatory, scientific and capital markets developments related to zervimesine and the company’s broader neurodegenerative disease pipeline.
Cognition Therapeutics (CGTX) recently released its second "Conversations" video podcast featuring experts discussing clinical data from the 2022 CTAD conference. The episode, moderated by Anthony Caggiano, M.D., focuses on insights from the lecanemab CLARITY study, emphasizing the importance of targeting amyloid oligomers for Alzheimer’s treatment. Cognition is advancing its lead candidate CT1812, targeting Alzheimer’s and related disorders, highlighting the necessity of innovative therapeutic approaches in neurodegenerative disease management.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced participation in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase, and BIO Partnering at JPM, taking place alongside the J.P. Morgan Annual Healthcare Conference 2023.
The events will feature panel discussions and corporate presentations on Alzheimer's and cognitive disorders, scheduled for January 8-9, 2023, in San Francisco, CA. The Cognition management team will meet with investors and pharmaceutical companies to discuss corporate achievements and clinical development strategies.
Cognition Therapeutics announced the expansion of its Phase 2 SHINE clinical trial for CT1812, an experimental Alzheimer's treatment, to include sites in Spain, the Netherlands, and the Czech Republic, in addition to the USA. The trial aims to enroll 144 participants and investigates CT1812's ability to prevent synaptotoxic effects caused by oligomers. Initial trials indicate potential cognition improvements and brain volume preservation. The study receives approximately $30 million in grant funding from the National Institutes on Aging.
Cognition Therapeutics (Nasdaq: CGTX) announced significant advancements regarding its Phase 2 trial for CT1812, targeting geographic atrophy due to dry age-related macular degeneration (dry AMD). With dry AMD affecting 10 million people in the U.S., the company emphasizes the need for effective treatments. CT1812, an oral sigma-2 receptor modulator, has shown promise in preclinical studies, demonstrating potential to rescue retinal pigment epithelial (RPE) functions impaired by oxidative stress. Cognition is in discussions with the FDA to initiate trials involving over 200 participants.
Cognition Therapeutics has announced the activation of up to 30 sites across the USA for its ongoing SHIMMER clinical trial evaluating CT1812, a novel treatment for dementia with Lewy bodies (DLB). This Phase 2 study aims to assess the safety and efficacy of CT1812, enrolling around 120 adults over six months. DLB currently lacks approved treatments, affecting approximately 1.4 million people in the U.S. The trial is supported by a $30 million grant from the National Institute on Aging and aims to provide crucial insights into cognitive and physical activity changes in DLB patients.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) recently completed its public offering, closing the sale of 5 million shares at $1.20 each, raising approximately $6 million in gross proceeds. The offering included a 30-day option for underwriters to purchase an additional 750,000 shares. The funds will support the development of its product candidates and general corporate purposes. Cantor Fitzgerald & Co. served as the sole book-running manager. This transaction is expected to enhance Cognition's financial position as it advances its clinical programs targeting Alzheimer's disease and related disorders.
Cognition Therapeutics (Nasdaq: CGTX) reported Q3 2022 financial results, showing a net loss of $6.6 million, or $0.29 per share, compared to a loss of $4.9 million in Q3 2021. The company continues to advance Phase 2 trials for CT1812, with enrollment for the SHINE study expanding into Europe. The SEQUEL trial received a $2.14M NIA grant to support enrollment completion. R&D expenses increased to $8.3 million due to trial activity, while general and administrative expenses rose to $4.4 million. Cash and equivalents stood at $46.6 million as of September 30, with $93.6 million in grants available.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced a public offering of 5,000,000 shares of common stock at $1.20 each, aiming for gross proceeds of approximately $6.0 million. The offering is set to close on November 15, 2022, pending customary conditions. Proceeds will fund the development of its product candidates and general corporate purposes. Cantor Fitzgerald & Co. is the sole book-running manager, with Newbridge Securities Corporation as co-manager. The SEC declared the registration statement effective on November 9, 2022.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) is recruiting participants for the SHIMMER Phase 2 clinical trial of CT1812, aimed at treating Lewy Body Dementia (LBD), with over 1.4 million Americans affected. This trial will include 120 adults aged 50 to 80 and analyze cognitive and physical changes over six months. Supported by $30M in NIH grants, the study is crucial given the lack of approved treatments for LBD. The company aims to raise awareness about this often-misdiagnosed condition during Lewy Body Dementia Awareness Month.
Cognition Therapeutics, Inc. (CGTX) has appointed Paul J. Tiseo, Ph.D., as vice president of clinical development. With over 20 years of experience in CNS drug development, Tiseo will oversee ongoing clinical studies for Alzheimer’s disease and dementia. The company is actively enrolling participants in three studies and plans to start additional studies soon. Tiseo expressed enthusiasm about enhancing development strategies for CT1812, a lead candidate targeting age-related degenerative disorders.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
